Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Gene | RET |
| Variant | C630R |
| Impact List | missense |
| Protein Effect | gain of function |
| Gene Variant Descriptions | RET C630R lies within the cysteine-rich region of the Ret protein (PMID: 9879991). C630R results in constitutive Ret phosphorylation and increased Ret kinase activity, formation of covalent Ret homodimers, and is transforming in cell culture (PMID: 9879991, PMID: 9230192). |
| Associated Drug Resistance | |
| Category Variants Paths |
RET mutant RET act mut RET C630R RET mutant RET C630X RET C630R |
| Transcript | NM_020975.6 |
| gDNA | chr10:g.43114488T>C |
| cDNA | c.1888T>C |
| Protein | p.C630R |
| Source Database | RefSeq |
| Genome Build | GRCh38/hg38 |
| Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
|---|---|---|---|---|---|
| NM_001406743.1 | chr10:g.43114488T>C | c.1888T>C | p.C630R | RefSeq | GRCh38/hg38 |
| NM_020630.5 | chr10:g.43114488T>C | c.1888T>C | p.C630R | RefSeq | GRCh38/hg38 |
| NM_020975.6 | chr10:g.43114488T>C | c.1888T>C | p.C630R | RefSeq | GRCh38/hg38 |
| NM_020630 | chr10:g.43114488T>C | c.1888T>C | p.C630R | RefSeq | GRCh38/hg38 |
| NM_020630.7 | chr10:g.43114488T>C | c.1888T>C | p.C630R | RefSeq | GRCh38/hg38 |
| NM_001406744.1 | chr10:g.43114488T>C | c.1888T>C | p.C630R | RefSeq | GRCh38/hg38 |
| NM_001406759.1 | chr10:g.43114488T>C | c.1888T>C | p.C630R | RefSeq | GRCh38/hg38 |
| NM_001406760.1 | chr10:g.43114488T>C | c.1888T>C | p.C630R | RefSeq | GRCh38/hg38 |
| NM_020975 | chr10:g.43114488T>C | c.1888T>C | p.C630R | RefSeq | GRCh38/hg38 |
| NM_020975.5 | chr10:g.43114488T>C | c.1888T>C | p.C630R | RefSeq | GRCh38/hg38 |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| RET C630R | medullary thyroid carcinoma | sensitive | Selpercatinib | FDA approved - On Companion Diagnostic | Actionable | In a Phase I/II trial (LIBRETTO-001) that supported FDA approval, Retevmo (selpercatinib) treatment resulted in an objective response rate (ORR) of 69% (38/55, 5 complete and 33 partial responses) in previously treated adult and pediatric patients of 12 years and older with medullary thyroid cancer harboring RET mutations as detected by an approved test, including RET C630R; ORR was 73% (64/88) in treatment naive patients (PMID: 32846061; NCT03157128). | detail... 32846061 detail... |